Clinical Trials Sponsored by Karyopharm Therapeutics Inc

Total 2977 results

GSO Global Clinical Research BV
Karyopharm Therapeutics Inc

Terminated

Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer (SENTINEL)

Colorectal Neoplasm

Germany, Belgium
Martin Gutierrez
Hackensack Meridian Health; Karyopharm Therapeutics Inc

Withdrawn

Selinexor Combination Ph 1 Study

Solid Tumor Malignancy

United States
GSO Global Clinical Research BV
Karyopharm Therapeutics Inc

Completed

A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (Relapsed/Refractory)

Germany
St. Jude Children's Research Hospital
Karyopharm Therapeutics Inc

Completed

Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia (AML) | Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS) | Mixed Phenotype Acute Leukemia (MPAL)

United States
Washington University School of Medicine
Karyopharm Therapeutics Inc

Completed

Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Washington University School of Medicine
Karyopharm Therapeutics Inc

Recruiting

Selinexor and Lenalidomide for Consolidation and Maintenance Treatment in Multiple Myeloma Post-transplant

Multiple Myeloma | Myeloma-Associated Amyloidosis

United States
Georgetown University
Hackensack Meridian Health; Karyopharm Therapeutics Inc

Terminated

Selinexor in Patients With Advanced Thymic Epithelial Tumor Progressing After Primary Chemotherapy (SELECT)

Thymoma | Advanced Thymic Epithelial Tumor

United States
St. Jude Children's Research Hospital
Karyopharm Therapeutics Inc

Terminated

Selinexor in Combination With Fludarabine and Cytarabine in Patients With Refractory or Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML)

United States
Weill Medical College of Cornell University
Karyopharm Therapeutics Inc

Terminated

Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients (ClaSPd)

Refractory Multiple Myeloma | Myeloma | Myeloma Multiple

United States
Weill Medical College of Cornell University
Karyopharm Therapeutics Inc

Withdrawn

Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease (STARR)

AL Amyloidosis | Amyloidosis | Amyloid

United States
University of Texas Southwestern Medical Center
Karyopharm Therapeutics Inc

Completed

Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

United States
Tulane University School of Medicine
Karyopharm Therapeutics Inc

Withdrawn

Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma (ESdRRMM)

Refractory Multiple Myeloma | Relapsed Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Millennium Pharmaceuticals, Inc.; Karyopharm Therapeutics Inc

Completed

A Study to Test the Combination of Selinexor (KPT-330), Ixazomib, and Dexamethasone in Patients With Myeloma

Multiple Myeloma | Relapsed and/or Refractory Multiple Myeloma

United States
Sanjay Mohan
AbbVie; Karyopharm Therapeutics Inc

Active, not recruiting

Venetoclax and Selinexor in Treating Patients With Relapsed or Refractory High Risk Hematologic Malignancies

Acute Myeloid Leukemia | Non-Hodgkin's Lymphoma | Diffuse Large B-cell Lymphoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI); Karyopharm Therapeutics Inc

Not yet recruiting

Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Relapsed Myelodysplastic Syndrome

United States
Alice Mims
Karyopharm Therapeutics Inc

Completed

Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
Kari Kendra
Karyopharm Therapeutics Inc

Completed

Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery (KPT-330)

Recurrent Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Karyopharm Therapeutics Inc

Completed

Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

Multiple Myeloma

United States
H. Lee Moffitt Cancer Center and Research Institute
Karyopharm Therapeutics Inc

Completed

Selinexor Plus High-Dose Melphalan (HDM) Before Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Multiple Myeloma

United States
H. Lee Moffitt Cancer Center and Research Institute
Karyopharm Therapeutics Inc

Completed

Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)

Breast Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Karyopharm Therapeutics Inc

Completed

Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

Acute Myeloid Leukemia | Leukemia

United States
Erin Bertino
Karyopharm Therapeutics Inc

Withdrawn

Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma
University of Colorado, Denver
National Cancer Institute (NCI); Karyopharm Therapeutics Inc

Recruiting

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma in Relapse

United States
H. Lee Moffitt Cancer Center and Research Institute
Karyopharm Therapeutics Inc

Terminated

SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Karyopharm Therapeutics Inc

Completed

A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML

Acute Myeloid Leukemia | Leukemia | AML

United States
Jennifer Woyach
Karyopharm Therapeutics Inc

Active, not recruiting

Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
Bhavana Bhatnagar
Karyopharm Therapeutics Inc

Completed

Decitabine and Selinexor in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia

United States
Erin Bertino
Karyopharm Therapeutics Inc

Terminated

Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer

Recurrent Small Cell Lung Carcinoma

United States
Canadian Cancer Trials Group
Roche Pharma AG; Janssen, LP; Karyopharm Therapeutics Inc

Recruiting

Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Lymphoma

Canada
St. Jude Children's Research Hospital
AbbVie; Gateway for Cancer Research; Karyopharm Therapeutics Inc

Recruiting

Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia, in Relapse | Acute Leukemia of Ambiguous Lineage in Relapse | Refractory Acute Leukemia of Ambiguous Lineage

United States
Mamta Parikh
National Cancer Institute (NCI); Karyopharm Therapeutics Inc

Recruiting

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Metastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Refractory Urothelial Carcinoma

United States
Dana-Farber Cancer Institute
Karyopharm Therapeutics Inc; William Lawrence and Blanche Hughes Foundation

Active, not recruiting

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

Relapsed Acute Lymphoblastic Leukemia (ALL) | Refractory Acute Lymphoblastic Leukemia (ALL) | Relapsed Acute Myelogenous Leukemia (AML) | Refractory Acute Myelogenous Leukemia (AML) | Relapsed Mixed Lineage Leukemia | Refractory Mixed Lineage Leukemia | Relapsed Biphenotypic Leukemia | Refractory... and other conditions

United States
Ida Bruun Kristensen
Odense Patient Data Explorative Network; Karyopharm Therapeutics Inc

Active, not recruiting

Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients (SABLe)

Multiple Myeloma

Denmark, Norway, Estonia
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center; Columbia University; Karyopharm Therapeutics Inc

Completed

Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Therapeutics, Inc.

Completed

Safety, Tolerability, and Pharmacokinetics of UHE-103 Cream in Subjects With Tinea Cruris and/or Tinea Pedis

Tinea Pedis | Tinea Cruris

United States
Therapeutics, Inc.

Completed

A Study of the Safety and Efficacy of UHE-105 Shampoo in Subjects With Scalp Psoriasis

Scalp Psoriasis

United States
Therapeutics, Inc.

Completed

A Phase 2 Safety and Efficacy Study of UHE-101 Cream in Subjects With Acne Vulgaris

Acne Vulgaris

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -305)

Plaque Psoriasis

United States
BlackThorn Therapeutics, Inc.
Neumora Therapeutics, Inc.

Completed

Study in Major Depressive Disorder With BTRX-335140 (NMRA-335140) vs Placebo

Major Depressive Disorder

United States
Sirion Therapeutics, Inc.
ReVision Therapeutics, Inc.

Completed

Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Geographic Atrophy | Dry Age Related Macular Degeneration
Hoffmann-La Roche
Tempest Therapeutics; Adagene Inc; Immune-Onc Therapeutics; NiKang Therapeutics...

Recruiting

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Advanced Liver Cancers

Korea, Republic of, Taiwan, United States, Israel, China, France, New Zealand
Therapeutics, Inc.

Completed

Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis

Tinea Pedis

United States, Puerto Rico

Clinical Trials Sponsored by Karyopharm Therapeutics Inc

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations